Antibiotice S.A. Logo

Antibiotice S.A.

Develops and manufactures generic medicines and APIs, specializing in anti-infectives.

ATB | RO

Overview

Corporate Details

ISIN(s):
ROATBIACNOR9
LEI:
315700P5G4O1L6GLMS02
Country:
Romania
Address:
VALEA LUPULUI, 707410 IAȘI
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Antibiotice S.A. is a pharmaceutical company specializing in the development and manufacturing of generic medicines. With a history of over 65 years, the company produces a diverse portfolio of products for human use, including finished dosage forms and Active Pharmaceutical Ingredients (APIs). Its offerings have a strong focus on anti-infectives, such as penicillin-derived products. The company operates eight GMP-certified manufacturing lines and holds U.S. FDA approvals for key products, including Nystatin (API), Ampicillin for injection, and Nafcillin. Antibiotice is committed to making valuable medicines accessible and affordable for patients and healthcare professionals, driven by continuous investment in research, quality, and the modernization of its manufacturing technologies.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-07 07:37
Report Publication Announcement
Raport curent de informare a investitorilor
Romanian 546.9 KB
2025-11-06 12:52
Post-Annual General Meeting Information
Raport curent de informare a investitorilor
Romanian 643.5 KB
2025-11-06 12:49
Post-Annual General Meeting Information
Raport curent de informare a investitorilor
Romanian 1.0 MB
2025-11-05 10:20
Pre-Annual General Meeting Information
Raport curent de informare a investitorilor
Romanian 291.4 KB
2025-10-03 11:39
Pre-Annual General Meeting Information
Convocarea adunarii generale a actionarilor - RC11
Romanian 1.4 MB
2025-10-03 11:38
Pre-Annual General Meeting Information
Raport curent de informare a investitorilor
Romanian 1.7 MB
2025-10-01 12:53
Pre-Annual General Meeting Information
Raport curent de informare a investitorilor
Romanian 2.4 MB
2025-09-23 08:35
Pre-Annual General Meeting Information
Convocarea adunarii generale a actionarilor - RC11
Romanian 1.4 MB
2025-09-17 15:12
Post-Annual General Meeting Information
Raport curent de informare a investitorilor
Romanian 949.8 KB
2025-09-04 12:29
Notice of Dividend Amount
Plata dividend - RC17
Romanian 2.1 MB
2025-08-13 12:27
Pre-Annual General Meeting Information
Convocarea adunarii generale a actionarilor - RC11
Romanian 1.4 MB
2025-08-06 12:40
Report Publication Announcement
Raport curent de informare a investitorilor
Romanian 137.7 KB
2025-07-24 12:07
Pre-Annual General Meeting Information
Convocarea adunarii generale a actionarilor - RC11
Romanian 1.6 MB
2025-07-09 12:28
Board/Management Information
Raport curent de informare a investitorilor
Romanian 491.4 KB
2025-07-01 11:49
Post-Annual General Meeting Information
Raport curent de informare a investitorilor
Romanian 606.7 KB

Automate Your Workflow. Get a real-time feed of all Antibiotice S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Antibiotice S.A.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Antibiotice S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Entrada Therapeutics, Inc. Logo
Developing intracellular therapeutics for rare neuromuscular diseases via its EEV™ platform.
United States of America TRDA
Develops novel therapeutics and APIs for oncology, inflammation, and respiratory diseases.
South Korea 183490
Enzymatica AB Logo
Develops medical devices with patented enzyme technology to treat upper respiratory infections.
Sweden ENZY
Developing alopecia therapies, skin regeneration products, and preclinical CRO services.
South Korea 446440
EQL Pharma AB Logo
Develops and sells cost-efficient niche generic medicines for the Nordic healthcare market.
Sweden EQL
Equillium, Inc. Logo
Clinical-stage biotech creating therapies for severe autoimmune and inflammatory disorders.
United States of America EQ
Erasca, Inc. Logo
Clinical-stage oncology company developing therapies targeting the RAS/MAPK pathway in cancer.
United States of America ERAS
Ernexa Therapeutics Inc. Logo
Developing targeted, off-the-shelf cell therapies for cancer and autoimmune diseases.
United States of America ERNA
ERYTECH Pharma S.A. Logo
Developing phage therapies to combat antibiotic-resistant bacterial infections.
France ERYP
Esperion Therapeutics, Inc. Logo
Develops oral ACLY inhibitors to lower high LDL-C and cardiovascular risk.
United States of America ESPR

Talk to a Data Expert

Have a question? We'll get back to you promptly.